TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
2상
완료
NCT00694629
| 대상 질환 | Pulmonary Tuberculosis |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Centers for Disease Control and Prevention |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 334 명 |
|---|
| 중재(약물) | rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg |
|---|
| 시작일 | 2008년 12월 |
|---|
| 완료일 | 2013년 6월 |
|---|
| 결과 공개일 | 2026년 7월 23일 |
|---|
요약
This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment. Participants were randomized to receive either a standard rifampin-based regimen (RHZE) or a rifapentine-substituted regimen (PHZE). An extension study evaluated higher daily doses of rifapentine (10, 15, and 20 mg/kg). The primary endpoint was sputum culture conversion at 8 weeks. Secondary outcomes included time to culture conversion, safety, and treatment discontinuation.
Participants With Negative Sputum Culture at 8 Weeks
8 weeks. · participants
| Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol | 52 participants |
|---|
| lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 62 participants |
|---|
| Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 59 participants |
|---|
| Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 54 participants |
|---|
Participants Who Discontinued Treatment During Intensive Phase
8 weeks · participants
| Standard Intensive-Phase TB Treatment: Rifampin (10 mg/kg) + Isoniazid + Pyrazinamide + Ethambutol | 11 participants |
|---|
| lRifapentine 10 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 5 participants |
|---|
| Rifapentine 15 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 5 participants |
|---|
| Rifapentine 20 mg/kg TB Treatment (PHZE): Isoniazid + Pyrazinamide + Ethambutol | 9 participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.